Shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) were up 0% during mid-day trading on Wednesday . The company traded as high as $2.38 and last traded at $1.56. Approximately 26,995,301 shares were traded during trading, an increase of 2,255% from the average daily volume of 1,146,255 shares. The stock had previously closed at $1.56.
A number of analysts have recently issued reports on CATB shares. Citigroup raised shares of Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Monday, November 20th. Zacks Investment Research raised shares of Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a report on Friday, January 26th. Finally, Wedbush reaffirmed an “outperform” rating and set a $4.00 price target on shares of Catabasis Pharmaceuticals in a report on Friday, December 15th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Catabasis Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $4.82.
The firm has a market capitalization of $28.85, a price-to-earnings ratio of -0.91 and a beta of 1.20.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/02/14/catabasis-pharmaceuticals-catb-trading-up-0.html.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.